Drug intelligence / Profile preview

Seresis

Development stage: Phase 2
Lead developer: Boehringer Ingelheim
Administration: Oral

Overview

Seresis is an innovative Swiss formula of natural antioxidants developed by Boehringer Ingelheim. It is marketed as a dietary supplement designed to protect the skin from premature aging by combating harmful free radicals and enhancing the skin's capacity to produce collagen and elastin. It aims to nourish the skin and support its ability to regenerate, helping to maintain its suppleness, health, and natural radiance. Clinical studies have investigated its antioxidant potency in the serum, skin, buccal mucosa cells, and plasma of healthy volunteers.

Brand names: Seresis

Beyond the preview

Go deeper on Seresis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seresis.

Explore the full profile